Chi-Med plans largest Chinese biotech listing on Nasdaq
This article was originally published in Scrip
Executive Summary
Hutchinson China MediTech (Chi-Med) is planning to spin off its R&D drugs business in what will be the largest Chinese biotech IPO on Nasdaq. The firm's CEO Christian Hogg told Scrip of his ambitious exit strategy as the diversified healthcare subsidiary of Hutchison Whampoa sharply cut its full-year net loss.